title: Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.
abstract: In vitro primary screening for identifying bioactive compounds (inhibitors, activators or pharmacological chaperones) against a protein target results in the discovery of lead compounds that must be tested in cell-based efficacy secondary screenings. Very often lead compounds do not succeed because of an apparent low potency in cell assays, despite an excellent performance in primary screening. Primary and secondary screenings differ significantly according to the conditions and challenges the compounds must overcome in order to interact with their intended target. Cellular internalization and intracellular metabolism are some of the difficulties the compounds must confront and different strategies can be envisaged for minimizing that problem. Using a novel screening procedure we have identified 15 compounds inhibiting the hepatitis C NS3 protease in an allosteric fashion. After characterizing biophysically the interaction with the target, some of the compounds were not able to inhibit viral replication in cell assays. In order to overcome this obstacle and potentially improve cellular internalization three of these compounds were complexed with γ-cyclodextrin. Two of them showed a five- and 16-fold activity increase, compared to their activity when delivered as free compounds in solution (while γ-cyclodextrin did not show antiviral activity by itself). The most remarkable result came from a third compound that showed no antiviral activity in cell assays when delivered free in solution, but its γ-cyclodextrin complex exhibited a 50% effective concentration of 5 μM. Thus, the antiviral activity of these compounds can be significantly improved, even completely rescued, using γ-cyclodextrin as carrier molecule.
authors.affiliation: Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain ; IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Claveria-Gimeno
authors.affiliation: Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: Vega
authors.affiliation: Instituto de Nanociencia de Aragon (INA), Universidad de Zaragoza, Zaragoza, Spain.
authors.forename: Valeria
authors.initials: V
authors.lastname: Grazu
authors.affiliation: Instituto de Nanociencia de Aragon (INA), Universidad de Zaragoza, Zaragoza, Spain ; Instituto de Ciencia de Materiales de Aragón (ICMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain ; Institute NanoBiomedicine and Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Jesús M
authors.initials: JM
authors.lastname: de la Fuente
authors.affiliation: IIS Aragón, Zaragoza, Spain ; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain ; Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain ; Department of Medicine, University of Zaragoza, Zaragoza, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Lanas
authors.affiliation: IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain ; Fundacion ARAID, Government of Aragon, Spain.
authors.forename: Adrian
authors.initials: A
authors.lastname: Velazquez-Campoy
authors.affiliation: Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain ; IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain ; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
authors.forename: Olga
authors.initials: O
authors.lastname: Abian
mesh_terms: D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D016174:Hepacivirus / Q000187:drug effects; D006801:Humans; D062105:Molecular Docking Simulation; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects; D047408:gamma-Cyclodextrins / Q000737:chemistry / Q000378:metabolism*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D000998:Antiviral Agents; D011480:Protease Inhibitors; D017361:Viral Nonstructural Proteins; D047408:gamma-Cyclodextrins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C023792:gamma-cyclodextrin
keywords: NS3 protease; antiviral compounds; cyclodextrins; drug activity; drug delivery; hepatitis C; primary and secondary screenings; vehiculization; virus replicon system
references.citation: Chem Rev. 1998 Jul 30;98(5):2045-2076
references.pmid: 11848959
references.citation: J Pharm Sci. 1997 Feb;86(2):147-62
references.pmid: 9040088
references.citation: J Med Chem. 2014 Mar 13;57(5):1673-93
references.pmid: 24446688
references.citation: Int J Pharm. 2007 Feb 1;329(1-2):1-11
references.pmid: 17137734
references.citation: Adv Drug Deliv Rev. 2007 Jul 30;59(7):645-66
references.pmid: 17601630
references.citation: N Engl J Med. 2011 Mar 31;364(13):1195-206
references.pmid: 21449783
references.citation: Nat Rev Microbiol. 2007 Jun;5(6):453-63
references.pmid: 17487147
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):17-28
references.pmid: 10837706
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):125-141
references.pmid: 10837712
references.citation: PLoS One. 2013 Jul 30;8(7):e69773
references.pmid: 23936097
references.citation: J Clin Virol. 2011 Dec;52(4):321-7
references.pmid: 21924672
references.citation: Nat Chem Biol. 2007 Aug;3(8):466-79
references.pmid: 17637779
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):41-57
references.pmid: 10837708
references.citation: J Biol Chem. 1998 Jul 24;273(30):18760-9
references.pmid: 9668049
references.citation: Gastroenterology. 2014 Mar;146(3):736-743.e1
references.pmid: 24262278
references.citation: J Control Release. 2007 Nov 6;123(2):78-99
references.pmid: 17888540
references.citation: Nat Rev Drug Discov. 2004 Dec;3(12):1023-35
references.pmid: 15573101
references.citation: Biophys J. 2010 Dec 1;99(11):3811-20
references.pmid: 21112306
references.citation: J Pharm Pharmacol. 2011 Sep;63(9):1119-35
references.pmid: 21827484
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: J Clin Invest. 2008 Aug;118(8):2858-67
references.pmid: 18596920
references.citation: Science. 1999 Jul 2;285(5424):110-3
references.pmid: 10390360
references.citation: J Hepatol. 2013 Mar;58(3):583-92
references.pmid: 23104162
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):81-99
references.pmid: 10837710
references.citation: Int J Mol Sci. 2013 Jun 26;14(7):13282-306
references.pmid: 23803659
references.citation: Anal Biochem. 1996 Aug 15;240(1):60-7
references.pmid: 8811880
references.citation: Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10
references.pmid: 18086851
references.citation: Nature. 2011 Jun 08;474(7350):S1
references.pmid: 21666726
references.citation: ACS Chem Biol. 2009 Nov 20;4(11):928-38
references.pmid: 19725577
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):101-123
references.pmid: 10837711
references.citation: N Engl J Med. 2011 Jun 23;364(25):2417-28
references.pmid: 21696308
references.citation: Carbohydr Res. 2007 Nov 5;342(15):2286-96
references.pmid: 17618611
references.citation: J Virol. 2002 Dec;76(24):13001-14
references.pmid: 12438626
references.citation: Proteins. 2009 Nov 15;77(3):624-36
references.pmid: 19536779
references.citation: J Phys Chem B. 2008 Feb 7;112(5):1445-50
references.pmid: 18193857
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):29-40
references.pmid: 10837707
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):59-79
references.pmid: 10837709
references.citation: Chem Rev. 1998 Jul 30;98(5):1875-1918
references.pmid: 11848952
references.citation: Chem Rev. 2007 Jul;107(7):3088-116
references.pmid: 17590054
references.citation: N Engl J Med. 2011 Mar 31;364(13):1207-17
references.pmid: 21449784
references.citation: Hepatology. 2014 Apr;59(4):1641-4
references.pmid: 24590916
references.citation: J Pharm Sci. 2003 Aug;92(8):1559-73
references.pmid: 12884243
references.citation: Biotechnol Adv. 2002 Dec;20(5-6):341-59
references.pmid: 14550020
references.citation: Antivir Ther. 2006;11(7):847-55
references.pmid: 17302247
references.citation: Nat Rev Drug Discov. 2003 May;2(5):369-78
references.pmid: 12750740